+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Retinopathy - Pipeline Insight, 2020

  • ID: 4989160
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 106 pages
  • DelveInsight
1 of 2
Diabetic Retinopathy Overview

Diabetic Retinopathy Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Retinopathy market. A detailed picture of the Diabetic Retinopathy pipeline landscape is provided, which includes the disease overview and Diabetic Retinopathy treatment guidelines. The assessment part of the report embraces in-depth Diabetic Retinopathy commercial assessment and clinical assessment of the Diabetic Retinopathy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Diabetic Retinopathy of pipeline development activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Diabetic Retinopathy treatment.
  • Diabetic Retinopathy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Diabetic Retinopathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Diabetic Retinopathy Analytical Perspective

In-depth Diabetic Retinopathy Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Diabetic Retinopathy Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Diabetic Retinopathy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Diabetic Retinopathy across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Diabetic Retinopathy therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Diabetic Retinopathy research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Diabetic Retinopathy .
Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Diabetic Retinopathy .
  • In the coming years, the Diabetic Retinopathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Diabetic Retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Diabetic Retinopathy treatment market. Several potential therapies for Diabetic Retinopathy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Diabetic Retinopathy market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Diabetic Retinopathy ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
  • What are the current options for Diabetic Retinopathy treatment?
  • How many companies are developing therapies for the treatment of Diabetic Retinopathy?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Diabetic Retinopathy?
  • How many Diabetic Retinopathy emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Diabetic Retinopathy?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Diabetic Retinopathy market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Diabetic Retinopathy?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Diabetic Retinopathy therapies?
  • What are the clinical studies going on for Diabetic Retinopathy and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Diabetic Retinopathy?
  • How many patents are granted and pending for the emerging therapies for the treatment of Diabetic Retinopathy?


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 2
1. Report Introduction

2. Diabetic Retinopathy
2.1. Overview
2.2. History
2.3. Diabetic Retinopathy Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Diabetic Retinopathy Diagnosis
2.6.1. Diagnostic Guidelines

3. Diabetic Retinopathy Current Treatment Patterns
3.1. Diabetic Retinopathy Treatment Guidelines

4. Diabetic Retinopathy - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Diabetic Retinopathy companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Diabetic Retinopathy Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Diabetic Retinopathy Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Diabetic Retinopathy Late Stage Products (Phase-III)

7. Diabetic Retinopathy Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diabetic Retinopathy Discontinued Products

13. Diabetic Retinopathy Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Diabetic Retinopathy Key Companies

15. Diabetic Retinopathy Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Diabetic Retinopathy Unmet Needs

18. Diabetic Retinopathy Future Perspectives

19. Diabetic Retinopathy Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll